Rapport Therapeutics stock retains a bearish daily bias after the close on Monday, October 19, 2026, at $28.6, with price sitting below all major exponential averages. Trial reports published after the close add a separate development. Monday’s completed chart does not capture the response to those reports. It opened at $27.57, traded between a low of $27.57 and a high of $29.10, and closed at $28.60, against a previous close of $27.57.
Key takeaways
- Rapport Therapeutics stock closed Monday at $28.6, below the 20-session EMA at $32.32, the 50-session EMA at $37.00, and the 200-session EMA at $35.67
- Daily RSI14 is 29.91, in oversold territory
- Daily MACD line is -3.43, above its signal at -3.49, with a positive histogram of 0.06
- The daily pivot for the next session sits at $28.42, with first resistance at $29.28 and first support at $27.75
- The close sits above the hourly 20-hour EMA at $28.43 and the 15-minute 20-period EMA at $28.39
Rapport Therapeutics Stock Holds Bearish Daily Structure
Rapport Therapeutics stock ended Monday’s session at $28.6, beneath the 20-session EMA at $32.32, the 50-session EMA at $37.00, and the 200-session EMA at $35.67. That positioning supports a bearish bias, although the averages are not fully stacked in bearish order.
Daily Momentum and Volatility Readings
Daily RSI14 stands at 29.91, in oversold territory. However, the MACD line of -3.43 sits above its signal at -3.49, with a positive histogram of 0.06. The crossover relationship supports the bullish case, but both lines remain below zero.
Meanwhile, the close sits between the daily lower Bollinger band at $25.84 and the mid-band at $31.82. The mid-band is an overhead reference before the 20-session EMA. Daily ATR14 reads $2.04, providing an absolute volatility measure rather than a directional signal.
Shorter Timeframes Complicate the Bearish Daily View
In contrast to the daily average positioning, Monday’s close sits above the hourly 20-hour EMA at $28.43 and Bollinger mid-band at $28.48. It remains below the 50-hour EMA at $29.18. The shorter timeframe therefore offers some support, but not confirmation of a bullish daily trend.
Hourly Chart Evidence
Hourly RSI14 is 50.27, just above neutral. The MACD line of -0.24 sits above its signal of -0.37, with a positive histogram of 0.13. Those readings favor the bullish side of the hourly balance, while the negative MACD line keeps the evidence mixed.
15-Minute Chart Context
For execution context, the close sits above the 15-minute 20-period EMA at $28.39 and 50-period EMA at $28.31. It remains below the 200-period EMA at $29.26 and upper Bollinger band at $28.89. These are quarter-hour averages, not daily trend measures.
At the same time, 15-minute RSI14 stands at 55.93, above neutral but below overbought territory. Its MACD line is 0.19, above the signal at 0.14, with a histogram of 0.05. ATR14 reads $0.28. This provides short-term timing context without overriding the daily bearish bias.
Trial News Follows Monday’s Close
Reports published on Tuesday, October 20, said Rapport’s bipolar mania drug met trial goals. A separate report that morning identified RAP-219 and described success in a mid-stage trial for adults with acute bipolar mania. These reports were published on Tuesday, after Monday’s session closed.
Key Levels and Scenarios for Rapport Therapeutics Stock
Next-Session Pivot Levels
Hourly and 15-minute pivots each sit at $28.75, with first resistance at $28.95 and first support at $28.39. These are reference levels when trading resumes.
Bullish and Bearish Scenarios
For the bullish scenario, holding the daily pivot at $28.42 and reclaiming the hourly pivot at $28.75 would support the constructive short-term readings. Clearing hourly first resistance at $28.95, then the hourly 50-hour EMA at $29.18, would strengthen that case. Beyond daily first resistance at $29.28, the daily mid-band at $31.82 and 20-session EMA at $32.32 remain overhead tests.
Conversely, a break below the daily pivot at $28.42 and hourly first support at $28.39 would undermine the initial bullish case. A break below daily first support at $27.75 and Monday’s low of $27.57 would reinforce the bearish reading. The daily lower Bollinger band at $25.84 is the next lower reference.
Overall, Rapport Therapeutics stock ended above the next-session daily pivot but below its daily averages. Daily ATR14 of $2.04 frames volatility, while the hourly and 15-minute signals provide only conditional support. The unresolved issue is how the next session’s price action relates to Tuesday’s trial reports and Monday’s technical levels.
FAQ
What is the daily trend structure for Rapport Therapeutics stock?
Rapport Therapeutics stock closed Monday at $28.6, below the 20-session EMA at $32.32, the 50-session EMA at $37.00, and the 200-session EMA at $35.67. This positioning supports a bearish bias, although the averages are not fully stacked in bearish order.
Is Rapport Therapeutics stock oversold on the daily chart?
Daily RSI14 stands at 29.91, which is in oversold territory. However, the daily MACD line of -3.43 is above its signal at -3.49 with a positive histogram of 0.06, presenting mixed momentum evidence as both MACD lines remain below zero.
What are the key levels to watch for Rapport Therapeutics stock?
The daily pivot for the next session sits at $28.42, with first resistance at $29.28 and first support at $27.75. Hourly and 15-minute pivots each sit at $28.75, with first resistance at $28.95 and first support at $28.39. The daily mid-band at $31.82 and 20-session EMA at $32.32 are overhead references.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.